ESMO: PFS, OS Extended With Divarasib in KRAS G12C-Mutated Advanced NSCLC

THURSDAY, Oct. 29, 2026-- Divarasib leads to significantly longer progression-free and overall survival than control treatment for patients with previously treated KRAS G12C-mutated advanced or metastatic non-small cell lung cancer (NSCLC)...